

3rd December 2010

Received
8/12/10.

The Manager
Office of Devices Authorisation
Therapeutic Goods Administration
P O Box 100
WODEN ACT 2606

Dear Sir,

Re: TGA Proposed Regulatory Reforms

Further to abovementioned subject matter, I wish to raise the following issues:-

Proposal 3(i) ARTG inclusion changes:-

The proposal obviously changes the existing arrangements and will cost a lot of time and energy. The "IT" costs for individual companies will be substantial both at the outset and the future.

Proposal 3(ii) Enhancing the Identification of approved devices:-

This proposal will increase the cost to us substantially and will increase the dispatch time to the client. I see this cost will need to be passed on – when you consider the many small consumables that we sell to the profession we see this proposal as impractical and expensive. The ongoing costs will also be significant and will eventually be borne by the end user – ie: the patient.

I trust that you take into consideration our input before your proposed regulatory reforms become reality.

Yours faithfully,
Ivoclar Vivadent Pty Ltd



Dr Peter Lobo
Executive Manager – Sales & Marketing

CC. Phil Jolly



IVOCLAR VIVADENT P/L ABN 26 004 280 273
Email: admin@ivoclarvivadent.com.au

HEAD OFFICE
1 – 5 Overseas Drive
Noble Park North VIC 3174
Tel (03) 9795 9599
Fax (03) 9795 9645

NEW SOUTH WALES
25 Cleg Street
Artarmon NSW 2064
Tel (02) 9436 0400
Fax (02) 9460 9082

QUEENSLAND
Unit 3 53 Southgate Avenue
Cannon Hill QLD 4170
Tel (07) 3899 8500
Fax (07) 3899 8599

WESTERN AUSTRALIA
134 Charles Street
West Perth WA 6005
Tel (08) 9227 1555
Fax (08) 9227 9855